Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [8217]

ECC 2013: Treating chest lymph nodes in patients with early breast cancer improves survival without increasing side effects

ECC 2013: Treating chest lymph nodes in patients with early breast cancer improves survival without increasing...

ECC 2013: Longest follow-up of largest number of melanoma patients treated with ipilimumab shows some survive up to ten years

ECC 2013: Longest follow-up of largest number of melanoma patients treated with ipilimumab shows some survive up...

ECC 2013: Anti-cancer drug T-DM1 benefits women with advanced breast cancer who have failed several previous treatments: results from TH3RESA trial

ECC 2013: Anti-cancer drug T-DM1 benefits women with advanced breast cancer who have failed several previous...

ECC 2013: New research shows how aspirin may act on blood platelets to improve survival in colon cancer patients

ECC 2013: New research shows how aspirin may act on blood platelets to improve survival in colon cancer patients

ECC 2013: New trial combining anti-cancer drug and radiotherapy may result in a new treatment for the most aggressive brain tumour

ECC 2013: New trial combining anti-cancer drug and radiotherapy may result in a new treatment for the most...

ECC 2013: Everolimus slows disease progression in advanced papillary kidney cancer patients

ECC 2013: Everolimus slows disease progression in advanced papillary kidney cancer patients

Repurposed antidepressants have potential to treat small-cell lung cancer

Repurposed antidepressants have potential to treat small-cell lung cancer

ECC 2013: Promising results for new antibody drug in non-small cell lung cancer

ECC 2013: Promising results for new antibody drug in non-small cell lung cancer

ECC 2013: Identifying disease-causing mechanisms in cancers with unknown primary site improves treatment and survival

ECC 2013: Identifying disease-causing mechanisms in cancers with unknown primary site improves treatment and...

Phase III START2 trial for tecemotide in stage III non-small cell lung cancer

Phase III START2 trial for tecemotide in stage III non-small cell lung cancer

More from ecancer